146 related articles for article (PubMed ID: 34622734)
1. Relapse prevention for alcohol use disorders: combined acamprosate and cue exposure therapy as aftercare.
Stryhn L; Larsen MB; Mejldal A; Sibbersen C; Nielsen DG; Nielsen B; Nielsen AS; Stenager E; Mellentin AI
Nord J Psychiatry; 2022 Jul; 76(5):394-402. PubMed ID: 34622734
[TBL] [Abstract][Full Text] [Related]
2. A Mobile Phone App Featuring Cue Exposure Therapy As Aftercare for Alcohol Use Disorders: An Investigator-Blinded Randomized Controlled Trial.
Mellentin AI; Nielsen B; Nielsen AS; Yu F; Mejldal A; Nielsen DG; Stenager E
JMIR Mhealth Uhealth; 2019 Aug; 7(8):e13793. PubMed ID: 31420960
[TBL] [Abstract][Full Text] [Related]
3. A randomized controlled study of exposure therapy as aftercare for alcohol use disorder: study protocol.
Mellentin AI; Nielsen B; Nielsen AS; Yu F; Stenager E
BMC Psychiatry; 2016 Apr; 16():112. PubMed ID: 27098817
[TBL] [Abstract][Full Text] [Related]
4. Cue exposure therapy for the treatment of alcohol use disorders: A meta-analytic review.
Mellentin AI; Skøt L; Nielsen B; Schippers GM; Nielsen AS; Stenager E; Juhl C
Clin Psychol Rev; 2017 Nov; 57():195-207. PubMed ID: 28781153
[TBL] [Abstract][Full Text] [Related]
5. Acamprosate in Korean alcohol-dependent patients: a multi-centre, randomized, double-blind, placebo-controlled study.
Namkoong K; Lee BO; Lee PG; Choi MJ; Lee E
Alcohol Alcohol; 2003; 38(2):135-41. PubMed ID: 12634260
[TBL] [Abstract][Full Text] [Related]
6. Cue exposure with coping skills training and communication skills training for alcohol dependence: 6- and 12-month outcomes.
Rohsenow DJ; Monti PM; Rubonis AV; Gulliver SB; Colby SM; Binkoff JA; Abrams DB
Addiction; 2001 Aug; 96(8):1161-74. PubMed ID: 11487422
[TBL] [Abstract][Full Text] [Related]
7. Naltrexone and cue exposure with coping and communication skills training for alcoholics: treatment process and 1-year outcomes.
Monti PM; Rohsenow DJ; Swift RM; Gulliver SB; Colby SM; Mueller TI; Brown RA; Gordon A; Abrams DB; Niaura RS; Asher MK
Alcohol Clin Exp Res; 2001 Nov; 25(11):1634-47. PubMed ID: 11707638
[TBL] [Abstract][Full Text] [Related]
8. Effects of D-cycloserine on extinction of mesolimbic cue reactivity in alcoholism: a randomized placebo-controlled trial.
Kiefer F; Kirsch M; Bach P; Hoffmann S; Reinhard I; Jorde A; von der Goltz C; Spanagel R; Mann K; Loeber S; Vollstädt-Klein S
Psychopharmacology (Berl); 2015 Jul; 232(13):2353-62. PubMed ID: 25697860
[TBL] [Abstract][Full Text] [Related]
9. The effects of acamprosate on alcohol-cue reactivity and alcohol priming in dependent patients: a randomized controlled trial.
Hammarberg A; Jayaram-Lindström N; Beck O; Franck J; Reid MS
Psychopharmacology (Berl); 2009 Jul; 205(1):53-62. PubMed ID: 19319508
[TBL] [Abstract][Full Text] [Related]
10. Naltrexone versus acamprosate: one year follow-up of alcohol dependence treatment.
Rubio G; Jiménez-Arriero MA; Ponce G; Palomo T
Alcohol Alcohol; 2001; 36(5):419-25. PubMed ID: 11524308
[TBL] [Abstract][Full Text] [Related]
11. Cue-exposure therapy to decrease alcohol craving in virtual environment.
Lee JH; Kwon H; Choi J; Yang BH
Cyberpsychol Behav; 2007 Oct; 10(5):617-23. PubMed ID: 17927528
[TBL] [Abstract][Full Text] [Related]
12. Pharmacologically induced alcohol craving in treatment seeking alcoholics correlates with alcoholism severity, but is insensitive to acamprosate.
Umhau JC; Schwandt ML; Usala J; Geyer C; Singley E; George DT; Heilig M
Neuropsychopharmacology; 2011 May; 36(6):1178-86. PubMed ID: 21289601
[TBL] [Abstract][Full Text] [Related]
13. The efficacy of cue exposure therapy on alcohol use disorders: A quantitative meta-analysis and systematic review.
Kiyak C; Simonetti ME; Norton S; Deluca P
Addict Behav; 2023 Apr; 139():107578. PubMed ID: 36563480
[TBL] [Abstract][Full Text] [Related]
14. Acamprosate and relapse prevention in the treatment of alcohol dependence: a placebo-controlled study.
Tempesta E; Janiri L; Bignamini A; Chabac S; Potgieter A
Alcohol Alcohol; 2000; 35(2):202-9. PubMed ID: 10787398
[TBL] [Abstract][Full Text] [Related]
15. United Kingdom Multicentre Acamprosate Study (UKMAS): a 6-month prospective study of acamprosate versus placebo in preventing relapse after withdrawal from alcohol.
Chick J; Howlett H; Morgan MY; Ritson B
Alcohol Alcohol; 2000; 35(2):176-87. PubMed ID: 10787394
[TBL] [Abstract][Full Text] [Related]
16. Pharmacologically controlled drinking in the treatment of alcohol dependence or alcohol use disorders: a systematic review with direct and network meta-analyses on nalmefene, naltrexone, acamprosate, baclofen and topiramate.
Palpacuer C; Duprez R; Huneau A; Locher C; Boussageon R; Laviolle B; Naudet F
Addiction; 2018 Feb; 113(2):220-237. PubMed ID: 28940866
[TBL] [Abstract][Full Text] [Related]
17. Role of Acamprosate and Baclofen as Anti-craving Agents in Alcohol Use Disorder: A 12-Week Prospective Study.
Sharma AK; Rikhari P; Shukla AK; Rikhari P
Cureus; 2024 Apr; 16(4):e58174. PubMed ID: 38741835
[TBL] [Abstract][Full Text] [Related]
18. Decline in cue-provoked craving during cue exposure therapy for smoking cessation.
Unrod M; Drobes DJ; Stasiewicz PR; Ditre JW; Heckman B; Miller RR; Sutton SK; Brandon TH
Nicotine Tob Res; 2014 Mar; 16(3):306-15. PubMed ID: 24078760
[TBL] [Abstract][Full Text] [Related]
19. Cue exposure for alcohol use disorders: A commentary on Kiyak et al. (2023).
Kavanagh DJ
Addict Behav; 2023 Sep; 144():107745. PubMed ID: 37146484
[TBL] [Abstract][Full Text] [Related]
20. New Australian guidelines for the treatment of alcohol problems: an overview of recommendations.
Haber PS; Riordan BC; Winter DT; Barrett L; Saunders J; Hides L; Gullo M; Manning V; Day CA; Bonomo Y; Burns L; Assan R; Curry K; Mooney-Somers J; Demirkol A; Monds L; McDonough M; Baillie AJ; Clark P; Ritter A; Quinn C; Cunningham J; Lintzeris N; Rombouts S; Savic M; Norman A; Reid S; Hutchinson D; Zheng C; Iese Y; Black N; Draper B; Ridley N; Gowing L; Stapinski L; Taye B; Lancaster K; Stjepanović D; Kay-Lambkin F; Jamshidi N; Lubman D; Pastor A; White N; Wilson S; Jaworski AL; Memedovic S; Logge W; Mills K; Seear K; Freeburn B; Lea T; Withall A; Marel C; Boffa J; Roxburgh A; Purcell-Khodr G; Doyle M; Conigrave K; Teesson M; Butler K; Connor J; Morley KC
Med J Aust; 2021 Oct; 215 Suppl 7():S3-S32. PubMed ID: 34601742
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
